RPLND stands for retroperitoneal lymph node dissection, a surgery that removes lymph nodes from the back of the abdomen to treat or stage testicular cancer. It targets the retroperitoneum, a space deep behind the intestines where lymph nodes sit along the body’s major blood vessels. These nodes are the first place testicular cancer tends to spread, making their removal a critical part of treatment for certain stages of the disease.
Why This Surgery Is Performed
RPLND serves two purposes at once: it removes lymph nodes that may contain cancer, and it gives doctors a definitive answer about whether the cancer has spread. Imaging scans can miss small deposits of disease, so examining the actual tissue under a microscope provides staging information that no scan can match.
The surgery is most commonly recommended for a type of testicular cancer called non-seminomatous germ cell tumors (NSGCT). The American Urological Association recommends it for stage IB disease and considers it an option for stage IA patients who don’t want to do long-term surveillance with repeated scans. It’s also recommended for stage IIA disease when blood tumor markers have returned to normal after the testicle has been removed. For patients whose primary tumor contained a type of tissue called teratoma with malignant transformation, RPLND is particularly important because teratoma doesn’t respond to chemotherapy and can only be treated surgically.
The other major role for RPLND is after chemotherapy. When chemo shrinks a tumor mass in the retroperitoneum but a residual lump larger than 1 cm remains on imaging, surgery is needed to remove whatever is left. In post-chemo specimens, about 72% of positive lymph nodes contain teratoma, tissue that would continue growing if left behind.
Open, Laparoscopic, and Robotic Approaches
The traditional approach is open surgery, which involves a long incision down the midline of the abdomen. This gives the surgeon direct access to the retroperitoneum and remains the standard for post-chemotherapy cases or when disease is more extensive.
Laparoscopic and robotic versions of the surgery use several small incisions and a camera. Compared to open surgery, these minimally invasive approaches result in less blood loss, shorter hospital stays, fewer complications, and faster recovery. Laparoscopic RPLND tends to have the shortest operating time of the three techniques. Robotic surgery, performed with the da Vinci system, offers enhanced precision and three-dimensional visualization but takes longer due to the setup and docking of the robotic arms, costs more, and carries a slightly higher risk of chylous leak (a lymphatic fluid complication).
The choice of approach depends on the clinical situation. Minimally invasive surgery works well for primary RPLND in early-stage disease. Post-chemotherapy cases, where scar tissue from chemo makes dissection more difficult and the stakes of missing residual disease are higher, are more often performed open, especially outside of highly specialized centers.
Surgical Templates and Thoroughness
Surgeons don’t remove every lymph node in the retroperitoneum. Instead, they follow a “template,” a mapped-out zone based on which side the original testicular tumor was on. For a right-sided tumor, the dissection extends to the inner edge of the aorta. For a left-sided tumor, it reaches to the inner edge of the large vein next to it (the vena cava).
Early versions of RPLND used very wide dissection boundaries, which controlled cancer effectively but caused high rates of nerve damage. Modified, narrower templates reduce that nerve damage substantially and have become standard for primary RPLND with low-volume disease. However, narrower templates carry a 3% to 23% risk of leaving behind undetected cancer in nodes outside the dissection zone. For post-chemotherapy RPLND, only very carefully selected patients at specialized centers should have a modified template, because the risk of missed disease is higher than in the primary setting.
Thoroughness matters for survival. A population-based analysis found that removing more than 40 lymph nodes during post-chemotherapy RPLND was associated with a 99% five-year cancer-specific survival rate, while removing 20 or fewer nodes corresponded to 91%. Each additional node removed was independently linked to better outcomes.
Nerve Damage and Ejaculation
The retroperitoneum contains sympathetic nerves that control ejaculation. Damage to these nerves during surgery can cause retrograde ejaculation, where semen travels backward into the bladder instead of out through the penis. This doesn’t affect the sensation of orgasm or the ability to achieve erections, but it does affect fertility.
Nerve-sparing techniques, where the surgeon identifies and preserves these nerve fibers during dissection, have dramatically improved outcomes. When performed as a bilateral (both-side) nerve-sparing procedure, published rates of preserved normal ejaculation range from 73% to 87%. Unilateral nerve-sparing RPLND, which only preserves nerves on one side, has a somewhat lower preservation rate of about 74%, compared to roughly 93% for bilateral sparing. Minimally invasive approaches appear to offer an additional advantage for nerve preservation. In one comparative study, the only patient who lost ejaculatory function was in the open surgery group.
Post-chemotherapy RPLND has lower preservation rates than primary surgery because chemotherapy-related scarring can make the nerves harder to identify and separate from surrounding tissue. One tertiary cancer center reported a 58% rate of preserved ejaculation after nerve-sparing post-chemo RPLND, lower than the 73% to 87% range seen in primary cases.
Fertility Planning Before Surgery
Because RPLND can affect ejaculation, and because many patients have already undergone chemotherapy that may have reduced sperm production, sperm banking before any cancer treatment is strongly recommended. Freezing sperm (cryopreservation) is safe, effective, and offers the best chance of fathering biological children in the future. It’s difficult to predict exactly how cancer treatment will affect any individual’s fertility, which is why banking should ideally happen before chemotherapy, radiation, or surgery begins. Even men who haven’t had chemo should consider it before RPLND, since the risk of ejaculatory changes is real.
Recovery After RPLND
Recovery depends heavily on whether the surgery was open or minimally invasive. Open RPLND involves a large abdominal incision, and patients typically spend several days in the hospital. Minimally invasive approaches generally mean a shorter stay and a quicker return to daily activities, though the exact timeline varies by individual and the extent of the dissection.
Regardless of approach, the early recovery period involves managing pain, gradually resuming eating, and slowly increasing physical activity. Heavy lifting and strenuous exercise are restricted for several weeks to allow the incision and internal tissues to heal.
Chylous Leak and Diet Restrictions
One complication specific to retroperitoneal surgery is chylous ascites, a leak of lymphatic fluid into the abdominal cavity. This happens when lymphatic channels are disrupted during node removal. The reported incidence ranges from about 1% to 7%, depending on the extent of surgery.
When a chylous leak occurs, the primary treatment is dietary. Patients are placed on a very low-fat diet, typically limiting intake to 0.5 grams of fat or less per serving. Eating less fat reduces the volume of chyle the body produces, which allows the leak to heal on its own. All foods must be prepared without butter, oil, or other added fats, and patients rely on fat-free versions of dairy and other staples. Fat-free nutritional supplements can help maintain calorie and protein intake during this period. Most chylous leaks resolve with this conservative approach over days to weeks.
Long-Term Outlook
Testicular cancer, even when it has spread to the retroperitoneal lymph nodes, has excellent cure rates. Five-year cancer-specific survival after post-chemotherapy RPLND reaches 91% to 99%, depending on how thorough the dissection is. For primary RPLND in early-stage disease, outcomes are even better. The surgery’s ability to both remove and definitively identify residual cancer makes it an irreplaceable part of the treatment pathway for many patients with non-seminomatous germ cell tumors.